Paper IV – Regulatory Affairs (MPH 104T)

(Common for 2017 and 2019 Scheme)

Time: 3 Hours

- Answer all questions to the point neatly and legibly Do not leave any blank pages between answers Indicate the question number correctly for the answer in the margin space
- Answer all parts of a single question together Leave sufficient space between answers
- Draw table/diagrams/flow charts wherever necessary.

Essays

- 1. Explain the NDA regulatory approval process in USFDA
- 2. Explain the general guidelines for developing non clinical drug development
- 3. Explain the pharmacovigilance safety monitoring in clinical trials

Short Notes

- 4. Explain the in-vitro performance in drug development
- 5. Explain the regulatory requirement of USFDA for biologics.
- 6. Explain the importance of eCTD in regulatory application submission.
- 7. Regulatory requirements of MHRA
- 8. Explain the dossier (IMPD)
- 9. Describe ICH guidelines for ICH-Q.
- 10. Explain informed consent process and procedures.
- 11. Explain drug master file
- 12. The concept about CRO to conduct BA/BE

QP CODE: 114327

(0) = AE

(3x10=30)

Total Marks: 75

(9x5=45)